Lapatinib Completed Phase 2 Trials for Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Squamous Cell Carcinoma of the Hypopharynx / Salivary Gland Squamous Cell Carcinoma / Recurrent Squamous Cell Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity / Stage IV Squamous Cell Carcinoma of the Oropharynx / Recurrent Metastatic Squamous Neck Cancer With Occult Primary / Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity / Stage IV Salivary Gland Cancer / Stage IV Verrucous Carcinoma of the Larynx / Head and Neck Carcinoma / Stage IV Squamous Cell Carcinoma of the Larynx / Recurrent Salivary Gland Cancer / Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma / Stage IV Verrucous Carcinoma of the Oral Cavity / Recurrent Verrucous Carcinoma of the Larynx / Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity / Recurrent Squamous Cell Carcinoma of the Hypopharynx / Recurrent Verrucous Carcinoma of the Oral Cavity / Recurrent Squamous Cell Carcinoma of the Oropharynx Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01044433Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck